416 related articles for article (PubMed ID: 28841377)
21. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
22. The effect of mutant GBA1 on accumulation and aggregation of α-synuclein.
Maor G; Rapaport D; Horowitz M
Hum Mol Genet; 2019 Jun; 28(11):1768-1781. PubMed ID: 30615125
[TBL] [Abstract][Full Text] [Related]
23. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice.
Oliveras-Salvá M; Macchi F; Coessens V; Deleersnijder A; Gérard M; Van der Perren A; Van den Haute C; Baekelandt V
Neurobiol Aging; 2014 Nov; 35(11):2625-2636. PubMed ID: 25037286
[TBL] [Abstract][Full Text] [Related]
24. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
Wang R; Sun H; Ren H; Wang G
Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
[TBL] [Abstract][Full Text] [Related]
25. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.
Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA
Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187
[TBL] [Abstract][Full Text] [Related]
26. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
27. Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson's disease.
de Oliveira GAP; Silva JL
Commun Biol; 2019; 2():374. PubMed ID: 31633065
[TBL] [Abstract][Full Text] [Related]
28. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein.
Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M
J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297
[TBL] [Abstract][Full Text] [Related]
29. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
30. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
Singh P; Bhat R
ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
[TBL] [Abstract][Full Text] [Related]
31. Wild-type α-synuclein inherits the structure and exacerbated neuropathology of E46K mutant fibril strain by cross-seeding.
Long H; Zheng W; Liu Y; Sun Y; Zhao K; Liu Z; Xia W; Lv S; Liu Z; Li D; He KW; Liu C
Proc Natl Acad Sci U S A; 2021 May; 118(20):. PubMed ID: 33972418
[TBL] [Abstract][Full Text] [Related]
32. Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders.
Ugras S; Daniels MJ; Fazelinia H; Gould NS; Yocum AK; Luk KC; Luna E; Ding H; McKennan C; Seeholzer S; Martinez D; Evans P; Brown D; Duda JE; Ischiropoulos H
EBioMedicine; 2018 May; 31():307-319. PubMed ID: 29759483
[TBL] [Abstract][Full Text] [Related]
33. Propagation of pathological α-synuclein in marmoset brain.
Shimozawa A; Ono M; Takahara D; Tarutani A; Imura S; Masuda-Suzukake M; Higuchi M; Yanai K; Hisanaga SI; Hasegawa M
Acta Neuropathol Commun; 2017 Feb; 5(1):12. PubMed ID: 28148299
[TBL] [Abstract][Full Text] [Related]
34. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
35. Familial Parkinson disease mutations influence α-synuclein assembly.
Ono K; Ikeda T; Takasaki J; Yamada M
Neurobiol Dis; 2011 Sep; 43(3):715-24. PubMed ID: 21684335
[TBL] [Abstract][Full Text] [Related]
36. (De)stabilization of Alpha-Synuclein Fibrillary Aggregation by Charged and Uncharged Surfactants.
Loureiro JA; Andrade S; Goderis L; Gomez-Gutierrez R; Soto C; Morales R; Pereira MC
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830391
[TBL] [Abstract][Full Text] [Related]
37. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states.
Fredenburg RA; Rospigliosi C; Meray RK; Kessler JC; Lashuel HA; Eliezer D; Lansbury PT
Biochemistry; 2007 Jun; 46(24):7107-18. PubMed ID: 17530780
[TBL] [Abstract][Full Text] [Related]
38. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
39. Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity.
Carija A; Pinheiro F; Pujols J; Brás IC; Lázaro DF; Santambrogio C; Grandori R; Outeiro TF; Navarro S; Ventura S
Redox Biol; 2019 Apr; 22():101135. PubMed ID: 30769283
[TBL] [Abstract][Full Text] [Related]
40. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S; Sarkar A; Sundar D
Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
